October 13, 2018

CORT: Corcept Therapeutics Incorporated Stock

by Wilton Risenhoover

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M)	7,649.00
Enterprise Value ($M)	7,559.18
Book Value ($M)	683.28
Book Value / Share	6.44
Price / Book	11.19
NCAV ($M)	275.33
NCAV / Share	2.60
Price / NCAV	27.78

Profitability (mra)
Return on Invested Capital (ROIC)	0.19
Return on Assets (ROA)	0.20
Return on Equity (ROE)	0.24

Liquidity (mrq)
Quick Ratio	2.96
Current Ratio	3.07

Balance Sheet (mrq) ($M)
Current Assets	438.50
Assets	846.46
Liabilities	163.17
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	675.04
Operating Income	136.95
Net Income	141.21
Earnings Per Share Basic And Diluted	n/a
Earnings Per Share Potentially Dilutive Securities Stock Options Outstanding	n/a
Earnings Per Share Diluted	n/a
Earnings Per Share Basic	n/a

Cash Flow Statement (mra) ($M)
Cash From Operations	198.07
Cash from Investing	-177.60
Cash from Financing	-28.35
(click for more detail)

File Date	Form	Activist 13D/G Investors	Ownership (%)	Change (%)
04-23	13G/A	BlackRock, Inc.	12.70	-18.64
02-21	13G/A	Ingalls & Snyder Llc	7.80	-1.07
02-14	13G/A	Belanoff Joseph K	6.30	3.65

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2025-05-05	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly peri
2025-02-26	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-10-30	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly peri
2024-07-29	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly peri
(click for more detail)

Short Volume
Market Date	Short Volume	Total Volume	Short Volume Ratio
2025-05-12	355,822	996,331	35.71
2025-05-09	276,074	828,085	33.34
2025-05-08	342,235	1,029,957	33.23
2025-05-07	460,529	1,101,754	41.80
(click for more detail)

Similar Companies
CNTX – Context Therapeutics Inc.	COCP – Cocrystal Pharma, Inc.
COEP – Coeptis Therapeutics Holdings, Inc.	COYA – Coya Therapeutics, Inc.
CPRX – Catalyst Pharmaceuticals, Inc.

Financial data and stock pages provided by
Fintel.io

Finpedia: Corcept Therapeutics

Related